CoChat

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Open access
Castella, Maria, Boronat, Anna, Martín-Ibáñez, Raquel, Rodríguez, Vanina, Suñé, Guillermo, Caballero, Miguel, Marzal, Berta, Pérez-Amill, Lorena, Martín-Antonio, Beatriz, Castaño, Julio, Bueno, Clara, Balagué, Olga, González-Navarro, Europa Azucena, Serra-Pages, Carles, Engel, Pablo, Vilella, Ramon, Benitez-Ribas, Daniel, Ortiz-Maldonado, Valentín, Cid, Joan, Tabera, Jaime, Canals, Josep M., Lozano, Miquel, Baumann, Tycho, Vilarrodona, Anna, Trias, Esteve, Campo, Elías, Menendez, Pablo, Urbano-Ispizua, Álvaro, Yagüe, Jordi, Pérez-Galán, Patricia, Rives, Susana, Delgado, Julio, Juan, Manel · 2019 · Molecular Therapy - Methods & Clinical Development
Cited by 126

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro , inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo , A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg- Prkdc scid Il2rd tm1Wjl /SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2018.11.010

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 126

Metadata

Authors
Castella, M., Boronat, A., Martín-Ibáñez, R., Rodríguez, V., Suñé, G., Caballero, M., Marzal, B., Pérez-Amill, L., Martín-Antonio, B., Castaño, J., Bueno, C., Balagué, O., González-Navarro, E. A., Serra-Pages, C., Engel, P., Vilella, R., Benitez-Ribas, D., Ortiz-Maldonado, V., Cid, J., Tabera, J., Canals, J. M., Lozano, M., Baumann, T., Vilarrodona, A., Trias, E., Campo, E., Menendez, P., Urbano-Ispizua, Á., Yagüe, J., Pérez-Galán, P., Rives, S., Delgado, J., & Juan, M.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2019-03
Volume
12
Pages
134-144
ISSN
2329-0501 (ISSN-L)
OpenAlex
W2904266952
Cited by
126
References
13
FWCI
3.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.